Engineering of Biomaterials for Drug Delivery Systems
Beyond Polyethylene Glycol
- 1st Edition - January 27, 2018
- Latest edition
- Editor: Anilkumar Parambath
- Language: English
Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol examines the combined issues of PEGylation and viable biomaterials as alternatives. With a strong… Read more
Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol examines the combined issues of PEGylation and viable biomaterials as alternatives. With a strong focus on polymeric biomaterials, the book first reviews the major issues associated with PEGylation and its use in vivo. Chapters then focus on alternative polymer systems for drug delivery systems. Finally, nanoparticles and future perspectives are examined. This book is a valuable resource for scientists and researchers in biomaterials, pharmaceuticals and nanotechnology, and all those who wish to broaden their knowledge in this field.
- Provides a self-contained work for the field of biomaterials for drug delivery
- Summarizes the current knowledge on PEGylation and strategies for bypassing it
- Presents research on an important, though under-represented issue in biomaterials
- Written by a world-class team of research scientists, engineers and clinicians
Researchers and scientists in biomaterials for drug delivery, biomaterials synthesis, pharmaceuticals and nanotechnology
1. PEGylated ‘stealth’ liposomes
2. PEGylated proteins
3. PEGylation and anti-PEG antibodies
4. Poly (zwitterions)
5. Poly (glycerols)
6. Poly (oxazolines)
7. Poly (aminoacids)
8. Poly (acylamides) and related systems
9. Poly (vinylpyrrolidones)
10. Sugar based systems (trehalose)
11. Polypeptide alternatives (PASylation and XTen) to PEG
12. DDS based on non-immunogenic biopolymers
13. Non-PEGylated nanoparticles
14. Summary and future perspectives
2. PEGylated proteins
3. PEGylation and anti-PEG antibodies
4. Poly (zwitterions)
5. Poly (glycerols)
6. Poly (oxazolines)
7. Poly (aminoacids)
8. Poly (acylamides) and related systems
9. Poly (vinylpyrrolidones)
10. Sugar based systems (trehalose)
11. Polypeptide alternatives (PASylation and XTen) to PEG
12. DDS based on non-immunogenic biopolymers
13. Non-PEGylated nanoparticles
14. Summary and future perspectives
- Edition: 1
- Latest edition
- Published: January 27, 2018
- Language: English
AP
Anilkumar Parambath
Dr Anilkumar Parambath is Senior R&D Manager of YTY Group, Indorama Corp., Perak, Malaysia. Prior to this, he was R&D Manager, Science & Technology at Unilever (2021-2024); Senior Manager and Head of Capsules Product R&D, ACG Capsules, Mumbai, India (2018-2021) and Principal Investigator for Performance and Specialty Materials at Syngene International Ltd, Bangalore India (2017-2018), where he worked on developing various elastomers, silicones, acrylics and other polymers for biomedical applications. He completed his PhD in Chemistry (Polymer Science) at the University of Kerala, India, and spent 7 years conducting post-doctoral research at Clemson University, USA, French atomic Energy Commission (CEA), France, and the University of British Columbia, Canada. HIs expertise is in polymer science, materials science, green chemistry, nanotechnology, nanomedicine, and biomaterials science. Dr. Parambath has edited three books on polymer biomaterials in drug delivery applications, including two with Elsevier, and has published many books chapters and journal articles. He has two patents to his name. In 2024, he was recognized by the American Chemical Society (ACS) as a Sustainability Star.
Affiliations and expertise
YTY Group, Indorama Corporation, Perak, MalaysiaRead Engineering of Biomaterials for Drug Delivery Systems on ScienceDirect